It's an investment on potential, they can't have any material knowledge to make investment decisions without bringing major heat down, definitely illegal. It's more likely they are investing in the potential of COVID and cancer treatment of adva-27a.
One thing I do wonder is if Aegis sees enough potential in developing the cancer generics to make enough profit to make it worth their while, and then making a calculated gamble on the covid treatment and adva-27a panning out in some capacity.
I can't remember how much the last annual report said they needed to progress their generics, but I think it was in the range of $2 million, and overall it was somewhere in the range of $20 million to fund all of their business ventures. Aegis is likely banking on that $2 billion (I think, maybe it was $1 billion) valuation from a few years back.
News 
Market Data 
Discover 
